Collaboration agreed
MilleGen SA has agreed a collaboration with Laboratoire Français du Fractionnement et des Biotechnologies SA (LFB), a supplier of pharmaceuticals to French hospitals, to design novel monoclonal antibodies that will more therapeutically effective and cheaper to manufacture.
The deal brings together MilleGen’s Directed Molecular Evolution platform with LFB’s know-how and expertise in therapeutic antibody discovery and development. MilleGen will apply its technology to genetically engineer the Fc region of the antibody as the first phase of the project. The second step will involve LFB in the pre-clinical evaluation of antibody candidates, in particular in cancers of the blood.
The project will also include academics at the Inserm laboratory in Toulouse France, who will be involved in the molecular and cellular engineering of recombinant antibodies.
Both partners obtained grants from the French government for the project under the Cancer BioSanté Midi Pyrénées programme.
Financial terms and conditions were not disclosed.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
